In its first quarterly statement since it began selling its AcuTect acute venous thrombosis agent, radiopharmaceutical firm Diatide last month reported fiscal and fourth-quarter (end-December) 1998 results. The Londonderry, NH, company’s year-end
In its first quarterly statement since it began selling its AcuTect acute venous thrombosis agent, radiopharmaceutical firm Diatide last month reported fiscal and fourth-quarter (end-December) 1998 results. The Londonderry, NH, companys year-end revenues were $6.4 million, compared with $4.1 million in 1997. The companys net loss for the year was $10.2 million, compared with $11 million the year before.
Diatides annual revenues for both 1997 and 1998 were primarily due to milestone payments from sales and marketing partner Nycomed Amersham. Nycomed paid Diatide $4 million in 1998, when it filed a new drug application for NeoTect, a lung cancer imaging agent, and when it received Food and Drug Administration clearance for AcuTect (SCAN 10/14/98). Diatides 1997 revenues included a $2 million milestone payment from Nycomed for Diatides NDA for AcuTect.
Diatides fourth-quarter revenues were $717,000, up from $510,000 the year before. Its net loss for the fourth quarter was $3.4 million, compared with $3.8 million in 1997. AcuTect contributed $177,000 to Diatides fourth-quarter revenues, a number that company executives acknowledged was disappointing. The firm attributed the slow start to the complexity of its marketing effort: In October AcuTect was introduced to physicians who make diagnoses, and in January it was presented to referring physicians.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.